Drug Type CAR-T |
Synonyms- |
Target |
Action inhibitors |
Mechanism T-cell surface glycoprotein CD5 inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory T Acute Lymphoblastic Leukemia | Phase 1 | China | 25 Oct 2022 |





